Back

Lipoprotein (a) and lipidemic parameters in PCSK-9 inhibitor patients. Experience from a specialized centre in Greece.

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Lp(a): the new risk factor Lipids ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Ioannis Andrikou

Hippokration General Hospital, Athens (Greece)

8 More presentations in this session

Presentation thumbnail
Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: design, rationale, and first results of the Zabrze-Lip(a)R Registry
Associate Professor K. Dyrbus (Zabrze, PL)
Abstract Slides Video
Presentation thumbnail
A sex-related analysis on the influence of lipoprotein(a) on primary cardiovascular disease prevention and its interplay with traditional lipid markers: results from a 20-year cohort study.
Miss E. Damigou (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Prognostic values of lipoprotein(a) levels for secondary prevention of acute coronary syndrome among patients who underwent primary percutaneous coronary intervention
Doctor R. Okubo (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Effects of lipid-lowering therapies on lipoprotein(a) levels in patients with dyslipidemia: a systematic review and network meta-analysis of 64 randomised controlled trials
Mr E. Loh (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Lipoprotein(a) levels and LPA genotypes are not associated with echocardiographic measures of left ventricular structure and function in the general population
Doctor A. Reimer Jensen (Gentofte, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Lp(a): the new risk factor

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Impact of Lp(a) on lipid control in patients with acute coronary syndrome
thumbnail
Congress Presentation
Two of a kind: mass and molar immunoassay-based lipoprotein (a) concentrations are similarly prognostic for MACE risk and predictive of alirocumab benefit in ODYSSEY OUTCOMES
thumbnail
Congress Presentation
Effects of lipid-lowering therapies on lipoprotein(a) levels in patients with dyslipidemia: a systematic review and network meta-analysis of 64 randomised controlled trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources